About Previse
Previse is a company based in Baltimore (United States) founded in 2018 by Dan Lunz and Stephen Meltzer was acquired by Castle Biosciences in May 2025. It operates as a HealthTech. Previse has raised $5.39 million across 3 funding rounds from investors including Castle Biosciences and National Institute of Diabetes and Digestive and Kidney Diseases. Previse offers products and services including Esopredict. Previse operates in a competitive market with competitors including PAVmed, Cyted, Lucid Diagnostics, BeamLine Diagnostics and CapNostics, among others.
- Headquarter Baltimore, United States
- Founders Dan Lunz, Stephen Meltzer
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Castle Biosciences
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.39 M (USD)
in 3 rounds
-
Latest Funding Round
$1.8 M (USD), Grant
Oct 11, 2023
-
Investors
Castle Biosciences
& 1 more
-
Employee Count
Not available
-
Acquired by
Castle Biosciences
(May 05, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Previse
Previse offers a comprehensive portfolio of products and services, including Esopredict.
Personalized guidance for Barrett’s esophagus surveillance is provided.
Funding Insights of Previse
Previse has successfully raised a total of $5.39M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.8 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Previse
Previse has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Castle Biosciences and National Institute of Diabetes and Digestive and Kidney Diseases.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research and health information on diabetes and kidney diseases are provided by NIDDK.
|
Locked | Locked | Locked | |
|
Diagnostic tests for cancer prognosis are provided.
|
Locked | Locked | Locked |
Investor details for Previse
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Previse
Investment portfolio details for Previse
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Previse
Detailed financials for Previse
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Previse Comparisons
Peer comparison for Previse
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Previse
Previse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PAVmed, Cyted, Lucid Diagnostics, BeamLine Diagnostics and CapNostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of medical devices and biomarkers to detect various diseases
|
|
| Locked | Locked | Locked |
Non-endoscopic diagnostics for early gastrointestinal disease detection are developed.
|
|
| Locked | Locked | Locked |
Diagnostic kits for esophageal cancer biomarkers are developed.
|
|
| Locked | Locked | Locked |
Offers bedside pre-screening technology solutions for cancer detection.
|
|
| Locked | Locked | Locked |
FDA-cleared swallowable device is used for non-endoscopic GI screening.
|
Detailed competitors of Previse
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Previse
Complete news archive for Previse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Previse
Previse was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Previse is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Dan Lunz is the current CEO of Previse. They have also founded this company.
Previse is a funded company, having raised a total of $5.39M across 3 funding rounds to date.
Solutions for earlier cancer detection are developed by Previse, focusing initially on esophageal cancer. Proprietary epigenetic biomarkers and data science are utilized to support diverse clinical studies globally. Precision medicine approaches are employed to predict and prevent cancer progression, particularly for conditions like Barretts esophagus. The healthcare sector is primarily targeted with innovative diagnostic tools.
Previse's top competitors include Lucid Diagnostics, PAVmed and Cyted.
Previse offers Esopredict.
Previse has 2 investors. Key investors include Castle Biosciences, and National Institute of Diabetes and Digestive and Kidney Diseases.